Biotech Values

[iwfal]

Where Feuerstein went wrong is in thinking that the proportion of patients who progressed according to primary-endpoint component X in the Satra arm vs the control arm was a valid estimator of time to progression according to component X in the Satra arm vs the control arm. This, of course, is mathematically nonsensical!

Got it. Thanks. But note that the proportion of patients whose death was the trigger for PFS is probably a good indicator of excess death due to the chemo itself. But I agree that the FDA will care more about overall death - i.e. it is ok to kill 10% of patients if you save 30%.

Clark